OraSure Technologies, Inc. (OSUR)
Nasdaq · Healthcare · Medical Instruments & Supplies
$4.11+3.66%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $284M
- 52-week range
- $2.08 – $4.58
- 52-week change
- +25.63%
- EPS (trailing)
- −$0.69
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $115M (−38.10%)
- Net income
- −$68.7M
- Operating margin
- −62.6%
- Diluted EPS
- −$0.94
- Free cash flow
- −$53.2M
From the company’s annual report on SEC EDGAR.
About OraSure Technologies, Inc.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device.
Headquarters: Bethlehem, United States · 500 employees · orasure.com